Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...

From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...

The FDA’s approval was supported by data from the PROGRESS study’s cohort 1. Credit: murat photographer/Shutterstock.com. The US Food and Drug Administration (FDA ...

At a confirmation hearing before the Senate, Overton stated the MMR vaccine is “safe and effective”, countering views from President Trump. Photo by: Daniel Heuer/Bloomberg via Getty Images. Dr Heidi ...

Henlius will oversee the candidates’ research, development, manufacturing and commercialisation worldwide. Credit: Gorodenkoff / Shutterstock.com. Amberstone Biosciences has signed a partnership and ...

Basecamp’s initial therapeutic focus is in vivo cell therapy, which involves reprogramming the cells of a patient inside the body. Credit: Basecamp Research. UK-based Basecamp Research has secured ...